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Halofantrine (HF) hydrochloride is commercially available only as oral dosage forms. Limitations of oral 
dosing of the drug coupled with non-availability of the safe parenteral preparations prompted the need 
to develop and evaluate suppository HF formulations, which may serve as a practical alternative. The 
effects of type of suppository base and incorporation of non ionic surfactants on in vitro release 
characteristics of HF from suppositories were investigated. The release rates were determined using a 
modification of the continuous flow bead-bed dissolution apparatus for suppositories. The results 
showed that the drug release from water-soluble base (polyethylene glycol) was significantly greater 
than that from lipophilic bases (Shea butter and Witepsol H15) (P <0.05). Incorporation of non ionic 
surfactants (Tweens 20 and 80, Spans 20 and 60) at different concentrations did not improve the in vitro 
availability of the drug from composite polyethylene glycol base (1500:4000, 80:20, w/w) suppositories. 
The extent of drug release was very low (maximum of 2.3%)  It is suggested that further studies are 
required for development of modalities to enhance the release of halofantrine from polyethylene glycol 
suppositories so as to optimize this dosage formulation of the drug.  
 





Halofantrine (HF) is a weakly basic and highly lipophilic 
(estimated log P, 8.5) 9-phenanthrenemethanol (Figure 
1) antimalarial drug available for oral administration as 
the hydrochloride salt. The drug has a place in the 
treatment of multi-resistant malaria including chloroquine-
resistant strains of Plasmodium falciparum (Weinke et al., 
1992; Karbwang and Na-Bangchang, 1994). The 
pharmacokinetics of HF is characterized by a low and 
highly variable oral absorption, and the mean oral 
bioavailability, which is further decreased in malaria 
patients, and is reported to be 4.7% (Karbwang et al., 
1991; Ajayi and Fleckenstein, 1994; Humberstone et al., 
1996). Although HF prolongs the QTc interval resulting in 
serious cardiotoxicity in predisposed individuals, it is still 
an important drug in the context of the continuing spread 




*Corresponding authors E-mail: faolad@oauife.edu.ng. Tel: +234 
08062691909 
Currently, only the oral formulations are available as 
tablets, suspensions and capsules of HF HCl. In some 
circumstances such as during nausea and vomiting or 
convulsion, or in uncooperative patients, oral route 
becomes impractical or even impossible. Another 
drawback associated with the oral administration of HF is 
its gastrointestinal side effects such as abdominal pain, 
diarrhea, nausea and constipation (Karbwang and Na-
Bangchang, 1994). Parenteral administration could serve 
as an alternative to the oral route for HF dosing but, an 
intravenous formulation of HF that has been tested 
clinically in humans was found to have adverse effects 
including severe local irritation as well as serious cardiac 
side effects (Krishna et al., 1993). A new intravenous 
nanocapsule formulation of HF has been investigated but 
its safety and efficacy in humans are yet to be 
established (Mosqueira et al., 2004). These limitations 
with the oral and new parenteral formulations of HF 
prompt the need for development and evaluation of 
suppository formulations of the drug, with the goal of 
introducing a practical alternative. There is no information  
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in the literature regarding the formulation of HF 
hydrochloride suppositories. The clinical value of rectal 
formulations has been demonstrated for various drugs 
such as analgesics, anticonvulsants, antiemetics, antiba-
cterial agents, non-steroidal anti-inflammatory drugs as 
well as antimalarials including artemisinin and its deriva-
tives (artesunate, artemether and dihydroartemisinin) 
(van Hoogdalem et al., 1991; Wilairatna et al., 2000; 
Karunajeewa et al., 2003).  
In general, rectal bioavailabilities tend to be lower than 
the corresponding oral values, except in some cases of 
partial avoidance of hepatic first-pass metabolism after 
rectal absorption. Since oral bioavailability of HF is low 
(Ajayi and Fleckenstein, 1994), it is reasonable to expect 
that rectal absorption of the drug will also be low. 
Improvements in drug absorption following rectal admini-
stration have been achieved by incorporation of absorp-
tion-promoting agents into suppositories (Van Hoogdalem 
et al., 1991; de Boer et al., 1990). Some absorption-
promoting agents, especially surfactants, have been 
shown to, not only enhance rectal drug absorption but 
also improve drug release from suppositories (Abdel-
Gawad et al., 1988; Nakanishi et al., 1994). Similar 
studies in our laboratories have demonstrated that incur-
poration of non-ionic surfactants (Tween 20, Tween 80 
and Brij 35) results in significant increase in the rate and 
extent of release of chloroquine from suppository formu-
lations (Onyeji et al., 1999). Since HF or its hydrochloride 
salt has very poor aqueous solubility (Humberstone et al., 
1996), its slow release from suppository formulations may 
be anticipated. Hence, an absorption enhancer that can 
improve the drug release has the potential of being more 
beneficial. Therefore, the objective of this study was to 
evaluate some suppository bases in order to determine 
bases capable of ensuring a rapid release of HF. Possi-
bility of improvement of the drug release by incorporation 










HF hydrochloride was extracted from Halfan® tablets (Smithkline 
Beecham, Lagos, Nigeria) following powdering the tablets and 
extraction with dichloromethane. The organic layer was evaporated 
to dryness and the product re-crystallized from aqueous methanol. 
Characterization of the extracted compound involved melting point 
determination, thin layer chromatography and U.V. analysis. The 
comparison of the values obtained  with those from reference 
halofantrine hydrochloride powder, kindly provided by Smithkline 
Beecham (Welwyn, United Kingdom), enabled the confirmation that 
the extracted compound was indeed HF. Polyethylene glycol (PEG) 
4000 and 1500 were purchased from British Drug House (B.D.H, 
United Kingdom). Other suppository bases included Witepsol H15 
(Dynamit-Nobel, Germany), and shea butter (obtained from a local 
market in Ile-Ife, Nigeria), and purified following established 
methods of Mital and Dove (1971). Tween 20® and Span 20® 
(BDH), Tween 80® (Sigma Chemical Co,. St Louis, USA) and Span 





A single factor was varied at each time and a minimum of three 
replications were made. In the first stage, the single factor varied 
was the suppository base, while all other factors (drug 
concentration, dissolution medium, temperature, dissolution 
apparatus and agitation) were kept constant. Three different 
suppository bases were used. Secondly, the single factor varied 
was the type of surfactant incorporated, while other factors as 
earlier indicated, in addition to the suppository base and surfactant 
concentration were kept constant. Four surfactants were used. 
Thirdly, the concentration of surfactants was the single factor that 
varied, all other parameters remained the same. 
 
 
Preparation of halofantrine suppositories 
 
HF hydrochloride suppositories containing 100 mg of the drug were 
prepared by the fusion method using a metal mould with six 
cavities. The composition of the bases was a blend of polyethylene 
glycols (PEG 1500, 80% w/w and PEG 4000, 20% w/w); Witepsol 
H15; and shea butter. Drug displacement values of the bases used 
were first determined and the amount of drug required was 
calculated. The drug powder was passed through a mesh sieve of 
100 µm prior to its incorporation into the base. Also, 100 mg of the 
drug with and without a surfactant (Tweens 20 and 80, Spans 20 
and 60) at concentrations indicated in Table 2 were added into the 
composite PEG base, using the displacement values calculated. 
 
  
Determination of release rates of drug and analysis of samples 
 
The method used for drug release determination was a modification 
(Onyeji et al., 1999) of the continuous flow bead-bed dissolution 
apparatus for suppositories earlier described by Roseman et al. 
(1981). The design of the method was such that it provided a 
reasonable control over the interfacial area during the dissolution, 
and this is a key factor in obtaining experimentally reproducible 
release data.  The release chamber consisted of a Gallen Kamp 
sinta glass No. 3 with the suppository enclosed in a bed of glass 
beads. The chamber was suspended in 400 ml, 0.1 M HCl in a 
1000 ml beaker, and the whole set-up was placed on a magnetic 






37 ± 1°C (Akala et al., 1991; Onyeji et al., 1999). Samples (4 ml 
each) were taken at specified time intervals for up to 180 min and 
assayed for HF. The volume of the dissolution medium was kept 
constant by replacing the withdrawn volume of the sample with 
equal volume of fresh dissolution medium maintained at the same 
temperature. A minimum of triplicate release rate determinations 
were made for each suppository preparation. 
HF samples were analysed using an ultraviolet spectrophoto-
metric method. A calibration curve was generated from a concentra-
tion range of the drug (0.25 to 8 µg/ml) prepared in 0.1 M HCl and 
UV absorbance measured at 254 nm. Following observation that 
HF suppository prepared with the composite PEG bases exhibited 
the best release characteristics, the formulation was subjected to 
pharmaceutical quality assessment following the British Pharmaco-
poeia (1988) tests. The mean content of the suppositories, deter-
mined using UV spectrophotometric method was 99 ± 2.4% (mean 
± SD). The uniformity of appearance, weight and content, as well as 
disintegration tests was evaluated. All the tests complied with the 





The extent of drug release was assessed from the total amount of 
drug present in the dissolution medium at the end of the 180 min 
drug release experiment. The type of drug release kinetics 
applicable for the suppository bases was determined by evaluation 
of three models, viz: zero-order kinetic model (Q vs t), diffusion-
controlled model (Q vs square-root of t) and first-order model 
(log(Qo – Q ) vs t), where Q is the amount of drug released at time 
‘t’ and Qo is the initial amount of the drug. The model that 
consistently produced the highest correlation among the 
suppository preparations was used for the assessment of drug 
release rates, and a slope obtained from linear regression analysis 
of the plot was determined as the drug release rate constant. The 
results expressed as mean ± SD were generated from replicate 
determinations for each suppository preparation. Analysis of 
variance for a randomized complete block design together with F-
test was conducted and comparison among treatment means was 
carried out using Duncan’s multiple range tests. 
 
 
RESULTS AND DISCUSSION 
 
Adequate characterization of drug release rate from 
suppositories requires the determination of its appropriate 
release kinetics model. Kinetics of drug release from 
suppositories may vary from zero-order through first-
order to diffusion-controlled. Plots of logarithm of the HF 
amounts remaining versus time for the suppository 
formulations with the three bases showed a linear rela-
tionship, with a correlation of not less 0.996 for only the 
hydrophilic base (polyethylene glycol). On the other hand, 
a straight line relationship was obtained when the drug 
amounts released was plotted against the square root of 
time for all the bases, with a correlation coefficient 
ranging from 0.98 to 0.99. This implies that the kinetics of 
release of HF from the hydrophilic bases can appropria-
tely be described by either a first-order or diffusion-
controlled model, while mainly diffusion-controlled mech-
anism governs the drug release from the lipophilic bases 
(Shea butter and Witepsol H15). Similar diffusion-control- 




led release mechanism has been reported for other 
antimalarial drugs such as amodiaquine hydrochloride 
and chloroquine phosphate (Akala et al., 1991; Onyeji et 
al., 1999).  
The mean extents and rates of release of HF from 
different suppository bases are shown in Table 1 with the 
drug release profiles depicted in Figure 2. While the 
release rate was significantly higher with PEG supposito-
ries than from either of the lipophilic bases (P < 0.05), the 
extents of release of HF in the bases were very poor. 
Such poor release characteristics are not likely caused by 
degradation of the drug or its interaction with the bases. 
Though incompatibilities of PEG, shea butter and 
Witepsol with some drugs have been reported (Boylan et 
al., 1986), the chemical class of drug to which HF 
belongs (Phenanthrine methanol with a tertiary amino 
group) has not exhibited any physical or chemical 
incompatibility with these bases (Lund, 1994; Crowley 
and Martini, 2002). Thus, the release pattern observed 
may be related to the solubility of HF in the bases, its 
diffusibility from them and its subsequent solubility in the 
dissolution medium.  HF hydrochloride is a lipophilic drug 
and its solubility in hydrophilic bases is expected to be 
low. Consequently, the drug has a higher tendency to 
diffuse out of hydrophilic bases. Another important factor 
that can influence the drug release is the water-absorbing 
property of the base which can facilitate penetration of 
the dissolution medium into the base with subsequent 
wetting and desorption of the embedded drug. The 
literature abounds with reports on improvement of disso-
lution of poorly water-soluble drugs from polyethylene 
glycol - based solid formulations and, this is due to the 
water-absorbing properties of polyethylene glycols with 
their subsequent solubility-enhancing effects (Khoo et al., 
2000; Emara et al., 2002). The finding in this study is 
consistent with other reports which show that polyethy-
lene glycol was found to be an optimal base for the 
formulation of suppositories containing poorly water-
soluble drugs (Usayapant and Iyer, 1999; Reglon et al., 
2001). It can therefore be asserted that the hydrophilic 
character of the suppository base promotes the release 
of HF. This assertion is further buttressed by the observa-
tion that Witepsol H15, with a hydroxyl value of <15 which 
is less than that of Shea butter (hydroxyl value of 30) 
(Odusote and Ifudu, 1987), has the lowest water-absor-
bing property and this reflected in the slowest drug 
release. In all the experiments in this study, the block or 
replication effect was not significant, indicating the repro-
ducibility of the suppository preparations and drug 
release. 
The results in Table 1 show that the rate of drug 
release correlates with the extent of release from the 
different bases. A maximum of only 2.25% of the drug 
was released from the polyethylene glycol suppositories 
within the 3-hr drug release experiment. It is apparent 
that this is attributable to the poor aqueous solubility of  




Table 1. Mean extents and rates of release of halofantrine hydrochloride from different 
suppository bases with each suppository preparation containing 100 mg of the drug. 
 











*Standard deviation values in parenthesis. 






























Figure 2. Release profiles of halofantrine from suppositories of 




the drug which has been reported to have a maximal 
solubility of 1.3 µg ml-1 in an aqueous system 
(Humberstone et al., 1996). In studies of mechanisms 
underlying in vitro availability of different drugs from 
suppositories, the water solubility of drugs was found to 
be the fundamental factor influencing the release rate 
and extent (Realdon et al., 2001). Different approaches 
have been used to improve solubility and dissolution rate 
of poorly water-soluble drugs from suppositories. These 
include solid dispersion and crystallization of the drug 
with carriers such as urea, sodium salicylates and beta-
cyclodextrin (Celebi et al., 1991; Usayapant and Iyer, 
1999; Sany et al., 2000) or through surfactant incorpora-
tion (Abd el-Gawad et al., 1988; Nakaishi et al., 1994). 
 In this study, the possibility of increasing the release of 
HF from suppositories was evaluated by incorporation of 
non-ionic surfactants with varied HLB values ranging 
from 4.7 to 16.7 into polyethylene glycol suppositories 
(Table 2). The different surfactants were compared at 
concentration of 4% (w/w) because that reflects the 
intermediate range of concentrations that have been 
found to be safe following rectal administration to humans 
(Davis et al., 1985; Van Hoogdalem et al., 1991). The 
release rates produced by Span 20 and Span 60 at 4% 
(w/w) concentration were not significantly different from 
that of the control (without adjuvants) (p > 0.05). On the 
other hand, the same concentrations of Tween 20 and 
Tween 80 resulted in significant decreases in drug 
release (p < 0.05). The effects of the surfactants were 
shown to be concentration-dependent (Table 2). For 
example, increasing the concentration of Span 60 from 4 
to 8% (w/w) was associated with a significant reduction in 
the drug release. Also, there was a progressive decrease 
in the release rate with increase in concentration of 
Tween 20. The drug release from suppositories 
containing Tween 20 at concentration of 2% (w/w) was 
not significantly different from that of the control (P > 
0.05) but the release reduced significantly at 4% and 
further diminished at 8% (w/w) incorporation. It was 
anticipated that the surfactants may decrease the 
interfacial tension between the drug and the dissolution 
medium with resultant improvement of drug solubility and 
subsequent release. An anionic surface-active agent, 
sodium taurocholate, has been shown to produce a 
significant enhancement of solubility and dissolution rate 
of halofantrine hydrochloride (Humberstone et al., 1996). 
Such a class of surfactants was not used in this study 
since they have low safety margins when applied 
internally. The non-improvement of the drug release by 
surfactants as observed is not unusual as other studies 
have revealed that incorporation of surfactants may 
increase or decrease drug release from suppositories 
(Ibrahim et al., 1980; Lee and Wang, 1999). The 
decrease in drug release at higher surfactant concentra-
tion as obtained is most likely attributable to micellar 
entrapment of the drug, resulting in retardation of the 
drug release. Although the surfactants at optimum 
concentration did not improve drug release, their incorpo-  




Table 2.  Mean extents and rates of release of halofantrine from composite polyethylene 
glycol (1500:4000; 80:20, w/w) suppositories containing different non ionic surfactants. 
 
Treatment Release rate constant 
(mg min-½ ) 
Extent of release 
(%) 
Control ( PEG with no surfactant) 
 
Tween 20 (4%, w/w) 
 
Tween 80 (4%, w/w) 
 
Span 20 (4%, w/w) 
 
Span 60 (4%, w/w) 
 
Span 60 (2%, w/w) 
 
Span 60 (8%, w/w) 
 
Tween 20 (2%, w/w) 
 






































Each suppository preparation contained 100 mg of halofantrine hydrochloride. 
*Standard deviation values in parenthesis. 




ration into the suppositories may still be useful since they 
have absorption-promoting effects.   
The pH of the dissolution medium used in this study 
(pH 1) does not reflect that of the rectal fluid (pH about 
7). An acidic pH was deliberately used after preliminary in 
vitro release experiments with the drug using water as 
the dissolution medium, revealed that the drug amounts 
released within the first one hour from lipophilic supposi-
tory bases yielded concentrations that were less than the 
limit of the UV spectrophotometric assay. This study 
being a formulation development investigation, it was 
rationalized that the use of a medium of pH 1 rather than 
that of pH 7 would not likely result in a change in the 
pattern of the influence of the type of suppository base 
and nature/amount of surfactant incorporated, on drug 
release. Rather, comparatively higher release rates and 
extents are expected in acidic dissolution medium since 
the drug is a weakly basic compound and, hence, more 
soluble at acidic pH. This point is premised on the fact 
that the penetration of the matrix of the suppository bases 
by an aqueous fluid and liquefaction or melting of the 
bases are not known to be influenced by an acidic pH of 
1. Also, the surfactants used being non ionic, are not 
affected by pH changes. However, the release rates 
obtained in this study may not have a direct in vivo 
significance due to the disparity in pH of the rectal and 
dissolution medium.  
In conclusion, a hydrophilic bases polyethylene glycol, 
was established to be superior to the lipophilic bases 
(shea butter and Witepsol H15) in terms of their ability to 
release HF from the suppository formulations. Incorpora-
tion of non ionic surfactants at different concentrations 
did not result in improvement of the drug release, which 
was a maximum of 2.3%. The low extent of in vitro 
availability of HF is most likely a major factor of the very 
poor water-solubility of the drug. There is a need for 
further studies to enhance HF release for optimization of 
polyethylene glycol suppository formulation of the drug. 
This may be achieved through development of modali-
ties, such as complexation with beta-cyclodextrin, for 
possible improvement of HF solubility. Further studies are 
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